

# AMENDMENTS TO THE SPECIFICATION

Please replace paragraph beginning on line 16, page 77, with the following amended paragraph:


In other embodiments, the ISS comprises any of the sequences:

5'-TGACCGTGAACGTTTCGAGATGA-3' (Sequence ID No. 2);  
 5'-TCATCTCGAACGTTCCACAGTCA-3' (Sequence ID No. 3);  
 5'-TGACTGTGAACGTTCCAGATGA-3' (Sequence ID No. 4);  
 5'-TCCATAACGTTTCGCCTAACGTTTCGTC-3' (Sequence ID No. 5);  
 5'-TGACTGTGAABGTTCCAGATGA-3' 5'-TGACTGTGAANGTTCCAGATGA-3' where  
 [[B]] N is 5-bromocytosine (Sequence ID No. 6); 5'-TGACTGTGAABGTTTCGAGATGA-3'  
 5'-TGACTGTGAANGTTTCGAGATGA-3', where [[B]] N is 5-bromocytosine (Sequence ID  
No. 7), and 5'-TGACTGTGAABGTTTCGAGATGA-3'  
 5'-TGACTGTGAANGTTTCGAGATGA-3', where [[B]] N is 5-bromocytosine (Sequence ID  
No. 8).

Please replace paragraph beginning on line 17, page 117, with the following amended paragraph:

**Scheme 1** is a non-limiting example of the preparation of a  $\beta$ -L-5'-aminoacyl-nucleoside derived from L-deoxyribonucleoside.


**Scheme 1**



Please replace paragraph beginning on line 5, page 119, with the following amended paragraph:

**Scheme 2** is a non-limiting example of the preparation of a  $\beta$ -L-3'-aminoacyl-nucleoside derived from L-deoxyribonucleoside.


**Scheme 2**



Please replace paragraph beginning on line 21, page 120, with the following amended paragraph:


**Scheme 3** is a non-limiting example of the preparation of a  $\beta$ -L-3',5'-di-aminoacyl-nucleoside derived from L-deoxyribonucleoside.

**Scheme 3**



Please replace paragraph beginning on line 21, page 121, with the following amended paragraph:

The title compounds can be made by optionally protecting any free amino in the heterocyclic or heteroaromatic base, for example N<sup>4</sup>-cytosine, N<sup>6</sup>-adenine or N<sup>2</sup>-guanine. For example, the amine can be protected by an acyl moiety or a dialkylaminomethylene moiety by the following general protocol.



Please enter the attached Sequence Listing into the Specification.

Attachments: Nucleotide Sequence Listing in written form (3 pp.)

Diskette containing the Sequence Listing in computer readable form

#### AMENDMENTS TO THE DRAWINGS

The attached sheets of drawings includes changes to Figures 1-6 and 16. These sheets, which includes Figures 1-7 and 16, replaces the original sheets including Figures 1-7 and 16. In Figures 1-6, previously omitted Figure 1a has been added; Figures 1b and 2-6 have been amended such that the 2'-deoxy- $\beta$ -L-cytidine has a 2'-deoxyribose sugar moiety; and Figure 16 has been amended such that it is now in compliance with 37 CFR 1.84 and 37 CFR 1.121.

Attachments: Replacement Sheets

Annotated Sheet Showing Changes